O	0	10	Randomized
O	11	16	phase
O	17	19	II
O	20	25	study
O	26	28	of
O	29	32	the
O	33	37	anti
O	37	38	-
O	38	47	epidermal
O	48	54	growth
O	55	61	factor
O	62	70	receptor
O	71	81	monoclonal
O	82	90	antibody
B-intervention	91	100	cetuximab
I-intervention	101	105	with
I-intervention	106	115	cisplatin
O	116	122	versus
B-control	123	132	cisplatin
I-control	133	138	alone
O	139	141	in
O	142	150	patients
O	151	155	with
O	156	166	metastatic
O	167	173	triple
O	173	174	-
O	174	182	negative
O	183	189	breast
O	190	196	cancer
O	196	197	.

O	198	207	Epidermal
O	208	214	growth
O	215	221	factor
O	222	230	receptor
O	231	233	is
O	234	247	overexpressed
O	248	250	in
O	251	261	metastatic
O	262	268	triple
O	268	269	-
O	269	277	negative
O	278	284	breast
O	285	292	cancers
O	293	294	(
O	294	300	mTNBCs
O	300	301	)
O	301	302	,
O	303	305	an
O	306	316	aggressive
O	317	324	subtype
O	325	327	of
O	328	334	breast
O	335	341	cancer
O	341	342	.

O	343	346	Our
O	347	357	randomized
O	358	363	phase
O	364	366	II
O	367	372	study
O	373	385	investigated
O	386	395	cisplatin
O	396	400	with
O	401	403	or
O	404	411	without
O	412	421	cetuximab
O	422	424	in
O	425	429	this
O	430	437	setting
O	437	438	.

B-eligibility	439	447	Patients
I-eligibility	448	451	who
I-eligibility	452	455	had
I-eligibility	456	464	received
I-eligibility	465	467	no
I-eligibility	468	472	more
I-eligibility	473	477	than
I-eligibility	478	481	one
I-eligibility	482	490	previous
I-eligibility	491	503	chemotherapy
I-eligibility	504	511	regimen
O	512	516	were
O	517	525	randomly
O	526	534	assigned
O	535	537	on
O	538	539	a
O	540	541	2
O	541	542	:
O	542	543	1
O	544	552	schedule
O	553	555	to
O	556	563	receive
O	564	566	no
O	567	571	more
O	572	576	than
O	577	580	six
O	581	587	cycles
O	588	590	of
O	591	600	cisplatin
O	601	605	plus
O	606	615	cetuximab
O	616	618	or
O	619	628	cisplatin
O	629	634	alone
O	634	635	.

O	636	644	Patients
O	645	654	receiving
O	655	664	cisplatin
O	665	670	alone
O	671	676	could
O	677	683	switch
O	684	686	to
O	687	696	cisplatin
O	697	701	plus
O	702	711	cetuximab
O	712	714	or
O	715	724	cetuximab
O	725	730	alone
O	731	733	on
O	734	741	disease
O	742	753	progression
O	753	754	.

O	755	758	The
O	759	766	primary
O	767	770	end
O	771	776	point
O	777	780	was
B-outcome-Measure	781	788	overall
I-outcome-Measure	789	797	response
I-outcome-Measure	798	802	rate
I-outcome-Measure	803	804	(
I-outcome-Measure	804	807	ORR
I-outcome-Measure	807	808	)
O	808	809	.

O	810	819	Secondary
O	820	823	end
O	824	830	points
O	831	838	studied
O	839	847	included
B-outcome-Measure	848	859	progression
I-outcome-Measure	859	860	-
I-outcome-Measure	860	864	free
I-outcome-Measure	865	873	survival
I-outcome-Measure	874	875	(
I-outcome-Measure	875	878	PFS
I-outcome-Measure	878	879	)
O	879	880	,
B-outcome-Measure	881	888	overall
I-outcome-Measure	889	897	survival
I-outcome-Measure	898	899	(
I-outcome-Measure	899	901	OS
I-outcome-Measure	901	902	)
O	902	903	,
O	904	907	and
B-outcome-Measure	908	914	safety
I-outcome-Measure	915	923	profiles
O	923	924	.

O	925	933	Analyses
O	934	942	included
O	943	944	a
O	945	957	significance
O	958	963	level
O	964	966	of
O	967	968	Î±
O	969	970	=
O	971	972	.
O	972	974	10
O	975	979	with
O	980	982	no
O	983	994	adjustments
O	995	998	for
O	999	1011	multiplicity
O	1011	1012	.

O	1013	1016	The
O	1017	1021	full
O	1022	1030	analysis
O	1031	1034	set
O	1035	1044	comprised
B-intervention-participants	1045	1048	115
O	1049	1057	patients
O	1058	1067	receiving
O	1068	1077	cisplatin
O	1078	1082	plus
O	1083	1092	cetuximab
O	1093	1096	and
B-control-participants	1097	1099	58
O	1100	1109	receiving
O	1110	1119	cisplatin
O	1120	1125	alone
O	1125	1126	;
O	1127	1129	31
O	1130	1138	patients
O	1139	1144	whose
O	1145	1152	disease
O	1153	1163	progressed
O	1164	1166	on
O	1167	1176	cisplatin
O	1177	1182	alone
O	1183	1191	switched
O	1192	1194	to
O	1195	1204	cetuximab
O	1204	1205	-
O	1205	1215	containing
O	1216	1223	therapy
O	1223	1224	.

O	1225	1228	The
B-outcome	1229	1232	ORR
O	1233	1236	was
B-iv-bin-percent	1237	1239	20
I-iv-bin-percent	1239	1240	%
O	1241	1242	(
O	1242	1244	95
O	1244	1245	%
O	1246	1248	CI
O	1248	1249	,
O	1250	1252	13
O	1253	1255	to
O	1256	1258	29
O	1258	1259	)
O	1260	1264	with
O	1265	1274	cisplatin
O	1275	1279	plus
O	1280	1289	cetuximab
O	1290	1293	and
B-cv-bin-percent	1294	1296	10
I-cv-bin-percent	1296	1297	%
O	1298	1299	(
O	1299	1301	95
O	1301	1302	%
O	1303	1305	CI
O	1305	1306	,
O	1307	1308	4
O	1309	1311	to
O	1312	1314	21
O	1314	1315	)
O	1316	1320	with
O	1321	1330	cisplatin
O	1331	1336	alone
O	1337	1338	(
O	1338	1342	odds
O	1343	1348	ratio
O	1348	1349	,
O	1350	1351	2
O	1351	1352	.
O	1352	1354	13
O	1354	1355	;
O	1356	1358	95
O	1358	1359	%
O	1360	1362	CI
O	1362	1363	,
O	1364	1365	0
O	1365	1366	.
O	1366	1368	81
O	1369	1371	to
O	1372	1373	5
O	1373	1374	.
O	1374	1376	59
O	1376	1377	;
O	1378	1379	P
O	1380	1381	=
O	1382	1383	.
O	1383	1385	11
O	1385	1386	)
O	1386	1387	.

O	1388	1397	Cisplatin
O	1398	1402	plus
O	1403	1412	cetuximab
O	1413	1421	resulted
O	1422	1424	in
O	1425	1431	longer
B-outcome	1432	1435	PFS
O	1436	1444	compared
O	1445	1449	with
O	1450	1459	cisplatin
O	1460	1465	alone
O	1466	1467	(
O	1467	1473	median
O	1473	1474	,
B-iv-cont-median	1475	1476	3
I-iv-cont-median	1476	1477	.
I-iv-cont-median	1477	1478	7
O	1479	1480	v
B-cv-cont-median	1481	1482	1
I-cv-cont-median	1482	1483	.
I-cv-cont-median	1483	1484	5
I-cv-cont-median	1485	1491	months
O	1491	1492	;
O	1493	1499	hazard
O	1500	1505	ratio
O	1506	1507	[
O	1507	1509	HR
O	1509	1510	]
O	1510	1511	,
O	1512	1513	0
O	1513	1514	.
O	1514	1516	67
O	1516	1517	;
O	1518	1520	95
O	1520	1521	%
O	1522	1524	CI
O	1524	1525	,
O	1526	1527	0
O	1527	1528	.
O	1528	1530	47
O	1531	1533	to
O	1534	1535	0
O	1535	1536	.
O	1536	1538	97
O	1538	1539	;
O	1540	1541	P
O	1542	1543	=
O	1544	1545	.
O	1545	1548	032
O	1548	1549	)
O	1549	1550	.

O	1551	1564	Corresponding
B-outcome	1565	1571	median
I-outcome	1572	1574	OS
O	1575	1578	was
B-iv-cont-median	1579	1581	12
I-iv-cont-median	1581	1582	.
I-iv-cont-median	1582	1583	9
O	1584	1590	versus
B-cv-cont-median	1591	1592	9
I-cv-cont-median	1592	1593	.
I-cv-cont-median	1593	1594	4
I-cv-cont-median	1595	1601	months
O	1602	1603	(
O	1603	1605	HR
O	1605	1606	,
O	1607	1608	0
O	1608	1609	.
O	1609	1611	82
O	1611	1612	;
O	1613	1615	95
O	1615	1616	%
O	1617	1619	CI
O	1619	1620	,
O	1621	1622	0
O	1622	1623	.
O	1623	1625	56
O	1626	1628	to
O	1629	1630	1
O	1630	1631	.
O	1631	1633	20
O	1633	1634	;
O	1635	1636	P
O	1637	1638	=
O	1639	1640	.
O	1640	1642	31
O	1642	1643	)
O	1643	1644	.

O	1645	1651	Common
B-outcome	1652	1657	grade
I-outcome	1658	1659	3
I-outcome	1659	1660	/
I-outcome	1660	1661	4
I-outcome	1662	1669	adverse
I-outcome	1670	1676	events
O	1677	1685	included
B-outcome	1686	1690	acne
I-outcome	1690	1691	-
I-outcome	1691	1695	like
I-outcome	1696	1700	rash
I-outcome	1700	1701	,
I-outcome	1702	1713	neutropenia
I-outcome	1713	1714	,
I-outcome	1715	1718	and
I-outcome	1719	1726	fatigue
O	1726	1727	.

O	1728	1733	While
O	1734	1737	the
O	1738	1745	primary
O	1746	1751	study
O	1752	1755	end
O	1756	1761	point
O	1762	1765	was
O	1766	1769	not
O	1770	1773	met
O	1773	1774	,
O	1775	1781	adding
O	1782	1791	cetuximab
O	1792	1794	to
O	1795	1804	cisplatin
O	1805	1812	doubled
O	1813	1816	the
O	1817	1820	ORR
O	1821	1824	and
O	1825	1833	appeared
O	1834	1836	to
O	1837	1844	prolong
O	1845	1848	PFS
O	1849	1852	and
O	1853	1855	OS
O	1855	1856	,
O	1857	1867	warranting
O	1868	1875	further
O	1876	1889	investigation
O	1890	1892	in
O	1893	1898	mTNBC
O	1898	1899	.
